Mind Medicine (MMQ) Price & Analysis

Compare

11 Followers

MMQ Stock Chart & Stats

€9.62

-€0.45(-5.84%)

At close: Jan 08 4:00 PM EST

€9.62

-€0.45(-5.84%)

Day’s Range― - ―

52-Week Range€4.29 - €12.21

Previous CloseN/A

Volume187.00

Average Volume (3M)429.00

Market Cap

$996.21M

Enterprise ValueN/A

Total Cash (Recent Filing)$209.07M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.26

Next Earnings

Mar 05, 2026

EPS Estimate

-0.44

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.67

Shares Outstanding98,509,280

10 Day Avg. Volume322

30 Day Avg. Volume429

Financial Highlights & Ratios

PEG Ratio0.12

Price to Book (P/B)2.03

Price to Sales (P/S)0.00

P/FCF Ratio-6.20

Enterprise Value/Market Cap0.00

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda0.00

Forecast

1Y Price Target

$26.75

Price Target Upside178.03% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering6

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical Trials ProgressThe Emerge Phase 3 trial for MM120 in major depressive disorder is enrolling faster than initially expected.

Financial PositionThe recent ~$259M financing extends the cash runway into 2028, and puts Mindmed in a strong financial position to execute on its pipeline.

Market OpportunityMNMD remains significantly undervalued as key Phase 3 data readouts for generalized anxiety disorder and major depressive disorder present great unmet need and significant market opportunity.

Bears Say

Mind Medicine News

Mind Medicine price target raised to $25 from $16 at Canaccord

Canaccord raised the firm’s price target on Mind Medicine (MNMD) to $25 from $16 and keeps a Buy...

3d ago

MNMD

Mind Medicine reports Q3 EPS (78c), consensus (50c)

“2025 continues to be a year of strong execution, and our recent $258.9 million financing further strengthens our...

3d ago

MNMD

Mind Medicine 18.375M share Spot Secondary priced at $12.25

Jefferies, Leerink and Evercore ISI acted as joint book running managers for the offering. Published first on TheFly...

11d ago

MNMD

Mind Medicine announces offering of common shares and warrants, no amount given

Mind Medicine (MNMD) announced that it intends to offer and sell, subject to market conditions, common shares and,...

11d ago

MNMD

Psychedelic: Needham initiates coverage of atai, GH Research, MindMed

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on...

24d ago

ABBV

ATAI

Mind Medicine initiated with an Outperform at LifeSci Capital

LifeSci Capital analyst Francois Brisebois initiated coverage of Mind Medicine (MNMD) with an Outperform rating and $32 price...

27d ago

MNMD

Mind Medicine initiated with a Buy at Needham

Needham analyst Ami Fadia initiated coverage of Mind Medicine (MNMD) with a Buy rating and $28 price target...

28d ago

MNMD

Mind Medicine’s Promising Clinical Progress and Strategic Advancements Justify Buy Rating

Analyst Francois Brisebois of LifeSci Capital reiterated a Buy rating on Mind Medicine, retaining the price target of...

3d ago

MNMD

Mind Medicine’s Accelerated Phase 3 Trials and Strong Financial Position Signal Promising Future

Analyst Ami Fadia from Needham reiterated a Buy rating on Mind Medicine and keeping the price target at...

3d ago

MNMD

MindMed Reports Q3 2025 Financial Progress

Mind Medicine Inc. ( ($MNMD) ) has released its Q3 earnings. Here is a breakdown of the information...

3d ago

MNMD

Mind Medicine Reports Q3 2025 Financial Results

An announcement from Mind Medicine ( ($MNMD) ) is now available. MindMed reported its Q3 2025 financial results...

3d ago

MNMD

MindMed Secures $259 Million in Public Offering to Advance Brain Health Innovations

Mind Medicine ( ($MNMD) ) has shared an update. Mind Medicine (MindMed) Inc. announced the successful closing of...

6d ago

MNMD

MindMed Issues Inducement Grants to New Employees

The latest update is out from Mind Medicine ( ($MNMD) ). MindMed announced the issuance of inducement grants...

6d ago

MNMD

Mind Medicine Completes Successful Public Offering

The latest announcement is out from Mind Medicine ( ($MNMD) ). On October 29, 2025, MindMed entered into...

10d ago

MNMD

MMQ FAQ

What was Mind Medicine’s price range in the past 12 months?

Mind Medicine lowest stock price was €4.29 and its highest was €12.21 in the past 12 months.

What is Mind Medicine’s market cap?

Mind Medicine’s market cap is $996.21M.

When is Mind Medicine’s upcoming earnings report date?

Mind Medicine’s upcoming earnings report date is Mar 05, 2026 which is in 115 days.

How were Mind Medicine’s earnings last quarter?

Mind Medicine released its earnings results on Nov 06, 2025. The company reported -€0.674 earnings per share for the quarter, missing the consensus estimate of -€0.433 by -€0.241.

Is Mind Medicine overvalued?

According to Wall Street analysts Mind Medicine’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Mind Medicine pay dividends?

Mind Medicine does not currently pay dividends.

What is Mind Medicine’s EPS estimate?

Mind Medicine’s EPS estimate is -0.44.

How many shares outstanding does Mind Medicine have?

Mind Medicine has 98,509,280 shares outstanding.

What happened to Mind Medicine’s price movement after its last earnings report?

Mind Medicine reported an EPS of -€0.674 in its last earnings report, missing expectations of -€0.433. Following the earnings report the stock price went same 0%.

Which hedge fund is a major shareholder of Mind Medicine?

Currently, no hedge funds are holding shares in DE:MMQ

Mind Medicine Stock Smart Score

Outperform

Fundamentals

Return on Equity

-85.59%

Trailing 12-Months

Asset Growth

-25.91%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Mind Medicine

Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders related to psychiatry, addiction, pain, and neurology. The company develops MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder, as well as for the treatment of chronic pain; and MM-110, an a3ß4 nicotinic cholinergic receptor antagonist that has completed phase 1 for the treatment of opioid withdrawal. It also develops MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine for the treatment of core symptoms of autism spectrum disorder. The company is headquartered in Vancouver, Canada.

Mind Medicine (MMQ) Earnings & Revenues

Historic Earnings Reports

MMQ Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Positive

The earnings call reflects a positive outlook for MindMed, driven by strong enrollment in pivotal trials, financial stability, and strategic leadership additions. However, increased R&D expenses present a financial challenge, although they are aligned with the company's growth and trial activities.View all DE:MMQ earnings summaries

MMQ Stock 12 Month Forecast

Average Price Target

€26.75

▲(178.03% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"€4","15":"€15","26":"€26","37":"€37","48":"€48"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":47.7152632,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€47.72</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26.7465738992,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€26.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":17.3510048,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€17.35</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,15,26,37,48],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.04,14.784251015384616,17.528502030769232,20.272753046153845,23.01700406153846,25.761255076923078,28.50550609230769,31.249757107692307,33.994008123076924,36.738259138461544,39.48251015384616,42.22676116923077,44.97101218461538,{"y":47.7152632,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.04,13.171274915323076,14.302549830646154,15.433824745969229,16.565099661292308,17.696374576615383,18.82764949193846,19.958924407261538,21.090199322584617,22.221474237907692,23.352749153230768,24.484024068553847,25.615298983876922,{"y":26.7465738992,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.04,12.44853883076923,12.85707766153846,13.265616492307691,13.674155323076922,14.082694153846152,14.491232984615383,14.899771815384614,15.308310646153846,15.716849476923075,16.125388307692305,16.533927138461536,16.942465969230767,{"y":17.3510048,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.72,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.935,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.505,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.89,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.475,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.6,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.18,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.09,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.04,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >